Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06366113
Recruiting Not applicable

Time of Exercise Re-training With Chronic Obstructive Pulmonary Disease (COPD)

NCT06366113 · tracked via the Priya Life Science France tracker
Sponsor
Michaël RACODON
Phase
Not applicable
Started
2024-01-02
Last updated
2026-01-12

Condition(s) studied

Respiratory Diseases

Investigational drug(s) / intervention(s)

Pulmonary rehabilitation

Pulmonary rehabilitation: Pulmonary rehabilitation includes : * Exercise re-training with resumption of physical activities * therapeutic patient education

Study summary

Pulmonary rehabilitation (PR) is an effective intervention for reducing hospital readmissions, secondary events, and mortality in patients with respiratory pathologies.

The program should not be improved by introducing new subjects such as circadian rhythm.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Patient with chronic obstructive pulmonary disease (COPD) * Registered for respiratory re-education and rehabilitation at the Clinique de la Mitterie * Number of rehabilitation sessions at least 18 over 4 weeks * Written informed consent signed by the patient * Membership of a social security Exclusion Criteria: * \- cardiovascular contraindications to exercise * unstable respiratory status (uncompensated respiratory acidosis) * conditions interfering with the pulmonary rehabilitation process (progressive neuromuscular disease, psychiatric illness)

Primary outcome measure(s)

  • 6-minute walk test (6MWT) — 15 minutes
    Walking distance in a test

Trial sites (1)

FacilityCityRegionStatus
Clinique la Mitterie Lille France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06366113 on ClinicalTrials.gov ↗ ← All trials in France